Pfizer shareholder meeting offers an inside look at the pharma industry
JUSTIN SULLIVAN/GETTY IMAGES
As Pfizer's board and shareholders celebrate stunning revenue and profits, it's time to ask why it's drugs cost so much. High R&D isn't the answer.
Suscribirse a:
Enviar comentarios (Atom)
.png)
No hay comentarios:
Publicar un comentario